Pexidartinib + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pigmented Villonodular Synovitis
Conditions
Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath, Tenosynovial Giant Cell Tumor
Trial Timeline
May 11, 2015 → Apr 30, 2021
NCT ID
NCT02371369About Pexidartinib + Placebo
Pexidartinib + Placebo is a phase 3 stage product being developed by Daiichi Sankyo for Pigmented Villonodular Synovitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02371369. Target conditions include Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath, Tenosynovial Giant Cell Tumor.
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02371369 | Phase 3 | Completed |
Competing Products
2 competing products in Pigmented Villonodular Synovitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| nilotinib | Novartis | Phase 2 | 35 |
| MCS110 + Placebo | Novartis | Phase 2 | 35 |